TY - JOUR AU - Thomson, Benjamin R. AU - Souma, Tomokazu AU - Tompson, Stuart W. AU - Onay, Tuncer AU - Kizhatil, Krishnakumar AU - Siggs, Owen M. AU - Feng, Liang AU - Whisenhunt, Kristina N. AU - Yanovitch, Tammy L. AU - Kalaydjieva, Luba AU - Azmanov, Dimitar N. AU - Finzi, Simone AU - Tanna, Christine E. AU - Hewitt, Alex W. AU - Mackey, David A. AU - Bradfield, Yasmin S. AU - Souzeau, Emmanuelle AU - Javadiyan, Shari AU - Wiggs, Janey L. AU - Pasutto, Francesca AU - Liu, Xiaorong AU - John, Simon W.M. AU - Craig, Jamie E. AU - Jin, Jing AU - Young, Terri L. AU - Quaggin, Susan E. T1 - Angiopoietin-1 is required for Schlemm’s canal development in mice and humans PY - 2017/12/01/ AB - Primary congenital glaucoma (PCG) is a leading cause of blindness in children worldwide and is caused by developmental defects in 2 aqueous humor outflow structures, Schlemm’s canal (SC) and the trabecular meshwork. We previously identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed that ANGPT/TEK signaling is essential for SC development. Here, we describe roles for the major ANGPT ligands in the development of the aqueous outflow pathway. We determined that ANGPT1 is essential for SC development, and that Angpt1-knockout mice form a severely hypomorphic canal with elevated intraocular pressure. By contrast, ANGPT2 was dispensable, although mice deficient in both Angpt1 and Angpt2 completely lacked SC, indicating that ANGPT2 compensates for the loss of ANGPT1. In addition, we identified 3 human subjects with rare ANGPT1 variants within an international cohort of 284 PCG patients. Loss of function in 2 of the 3 patient alleles was observed by functional analysis of ANGPT1 variants in a combined in silico, in vitro, and in vivo approach, supporting a causative role for ANGPT1 in disease. By linking ANGPT1 with PCG, these results highlight the importance of ANGPT/TEK signaling in glaucoma pathogenesis and identify a candidate target for therapeutic development. JF - The Journal of Clinical Investigation JA - J Clin Invest SN - 0021-9738 DO - 10.1172/JCI95545 VL - 127 IS - 12 UR - https://doi.org/10.1172/JCI95545 SP - 4421 EP - 4436 PB - The American Society for Clinical Investigation ER -